Kenvue is like the Procter & Gamble for health and personal care brands.

• Tylenol: Over-the-counter medication for pain relief and fever reduction.
• Neutrogena: A range of skincare, haircare, and cosmetics products.
• Listerine: Oral care products, primarily antiseptic mouthwash.
• Johnson's: A line of baby care and personal care products.
• Band-Aid: Brand of adhesive bandages and wound care products.
• Aveeno: Skincare and body care products, often focused on natural ingredients.
• Zyrtec: Over-the-counter medication for allergy relief.
• Nicorette: Products designed to help individuals quit smoking, primarily nicotine replacement therapy.

Kenvue (KVUE) sells primarily to other companies, specifically various retail organizations. The company's portfolio of iconic brands, including Tylenol, Neutrogena, Listerine, Johnson’s, Band-Aid, Aveeno, Zyrtec, and Nicorette, are made available to individual consumers through these retail channels.

While the background information confirms that Kenvue engages in "data-driven customer partnerships" with its "retail customers," it does not list the specific names of these major customer companies or their public symbols. Therefore, specific customer company names cannot be provided from the given text.

1. Kenvue faces risks associated with its separation from Johnson & Johnson, as it was incorporated in connection with the separation and was a wholly-owned subsidiary of Johnson & Johnson prior to its offering. This transition may involve challenges in establishing independent operations, systems, and supply chains, and could lead to the loss of benefits previously derived from being part of a larger, diversified parent company.

2. The company operates in a highly competitive global consumer health market, which is expected to grow at a compounded annual growth rate of 3% to 4% globally through 2025. Maintaining leadership positions and adapting to evolving consumer preferences in this dynamic and large market, valued at $369 billion, requires continuous innovation, effective marketing, and strategic responses to competitive pressures.

3. Kenvue's business is significantly dependent on a concentrated portfolio of iconic brands, with ten of its brands generating approximately $400 million or more in net sales in 2022, and holding seven #1 brand positions across major categories globally. While a strength, this concentration means that any adverse events affecting these key brands, such as product recalls, reputational damage, or increased competition, could have a disproportionately significant impact on the company's financial performance.

Kenvue operates within a global consumer health market with an addressable size of $369 billion. This market is expected to grow at a compounded annual growth rate of 3% to 4% globally through 2025.

Kenvue (KVUE) anticipates several key drivers for its future revenue growth over the next 2-3 years:

1. Value Realization through Pricing and Mix Management: The company expects to drive organic sales growth through a combination of strategic pricing adjustments and optimizing its product mix towards higher-value offerings. This "value realization" has been a consistent component of its organic sales growth outlook.
2. Increased Brand Investments and Marketing: Kenvue is actively increasing its investments in brand marketing, including engagement with healthcare professionals and direct consumer initiatives, to bolster brand strength and fuel growth. This strategy aims to enhance consumer connection and drive demand for its portfolio of iconic brands.
3. Supply Chain Efficiency and Productivity Gains: Improvements in supply chain efficiency and broader productivity initiatives are expected to contribute to adjusted gross profit margin expansion. These operational enhancements can indirectly support revenue growth by allowing for strategic investments in the business or by enabling competitive pricing.
4. Strong Performance in the Essential Health Segment: The Essential Health segment has consistently shown robust organic growth across various categories and geographical regions. This segment is expected to continue to be a significant contributor to Kenvue's overall revenue expansion.
5. Operational Transformation and Exit from Transition Service Agreements (TSAs): Kenvue's ongoing efforts to improve productivity, reduce costs, and fully exit Transition Service Agreements (TSAs) are designed to enhance operational focus and free up resources. This greater autonomy and efficiency are aimed at supporting core growth strategies.

Share Repurchases

• Kenvue's stated capital allocation priorities include share buybacks to offset dilution.
• The company did not make any share buybacks in the fourth quarter of 2025.

Share Issuance

• Kenvue completed its Initial Public Offering (IPO) in May 2023, raising $3.8 billion.
• During the IPO, Kenvue offered 198.7 million shares at $22.00 per share, including the underwriters' full exercise of their over-allotment option.
• Johnson & Johnson completed the disposition of an additional 80.1% of Kenvue's outstanding common stock in August 2023, transitioning Kenvue to a fully independent public company.

Capital Expenditures

• Kenvue's capital expenditures were $0.4 billion in 2024 and increased to $0.5 billion in 2025.
• The company initiated the "Our Vue Forward" program, incurring approximately $550 million in restructuring costs split between 2024 and 2025, to optimize its geographic footprint, reduce redundancies, and implement new systems.
• Capital investments are directed towards areas such as innovation, research and development (R&D), and enhancing its digitally connected supply chain ecosystem.